常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.16/1.00
|
|
企业价值
63.14M
|
| 资产负债 |
|
每股账面净值
7.15
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
2.13M
|
|
每股收益
1.04
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/15 03:01 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. |

13 
